All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @lizglpguide on TikTok · 91s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @lizglpguide's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00You are slowing down your progress by not doing these things.
  2. 0:02Scale suddenly froze and you're like,
  3. 0:04is my jail P1 not working anymore?
  4. 0:06It is!
  5. 0:07Uhh...
  6. 0:08Maybe you dropped the ball a little bit.
  7. 0:10These mistakes are blocking your results.
  8. 0:12Everybody thinks that as soon as they get a stall,
  9. 0:14they think, oh, I should go up on my dose.
  10. 0:17No, most stalls are actually behavioral and not biological.
  11. 0:21You're not eating enough protein. I almost guarantee it.
  12. 0:23jail P1's killer appetite.
  13. 0:26So low protein equals slower metabolism,
  14. 0:28which equals stall results.
  15. 0:30And then you're not moving enough because you're not eating enough.
  16. 0:34Fat loss isn't just calories.
  17. 0:36So even if you stop doing less activity,
  18. 0:38like moving around the house,
  19. 0:39I'm not even talking about exercise.
  20. 0:41Your metabolism is going to adapt to that.
  21. 0:44And it's going to slow.
  22. 0:45If you don't know me, my name's Liz.
  23. 0:46I'm a PA.
  24. 0:47I'm a jail P1 user and I also run something called
  25. 0:49a gen GLP club.
  26. 0:50If you don't know about that yet,
  27. 0:51you're just weird.
  28. 0:53And I hope you live on jail P's.
  29. 0:54I feel like gross.
  30. 0:56You are scale obsessed.
  31. 0:58GLP 1's change inflammation.
  32. 1:00They change water weight.
  33. 1:01They change digestion.
  34. 1:03Your scale lies before it tells the truth.
  35. 1:06That sounded good, didn't it?
  36. 1:07You think the medication does all the work for you.
  37. 1:09But GLP 1's are a tool.
  38. 1:11Remember?
  39. 1:11You're not the strategy.
  40. 1:13Habits still matter.
  41. 1:14Studies show that GLP 1 users who prioritize protein
  42. 1:18and resistance training have more fat loss
  43. 1:21and they keep it off longer.
  44. 1:22So all of a sudden you're failing.
  45. 1:24It just means that your body is adapted
  46. 1:26and you need to adapt back.
  47. 1:28She went just with someone on a GLP 1
  48. 1:29who thinks their medicine stopped working.

GLP-1 weight loss plateaus: what actually causes them?

Liz | GLP💉Coach

TikTok creator

129.8K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists like semaglutide and tirzepatide reduce appetite significantly, which can inadvertently lead to inadequate protein intake and reduced physical activity, both of which contribute to lean mass loss and metabolic slowdown during weight loss. Weight plateaus in this context often reflect a combination of adaptive thermogenesis, reduced non-exercise activity, and suboptimal dietary composition rather than medication failure alone. Clinicians generally recommend structured protein targets and resistance training alongside GLP-1 therapy to preserve muscle mass and support long-term weight maintenance.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For GLP-1 weight loss plateaus: what actually causes them?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

GLP-1 weight loss plateaus: what actually causes them? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "GLP-1 weight loss plateaus: what actually causes them?" from Liz | GLP💉Coach. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide reduce appetite significantly, which can inadvertently lead to inadequate protein intake and reduced physical activity, both of which contribute to lean mass loss and metabolic slowdown during weight loss.

The reason this review is not generic is the source wording and the canonical claim label "glp1 struggling with the glp 1 weight loss stall glp one plateaus." In this clip, the useful excerpt is: "You are slowing down your progress by not doing these things." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Research supports protein targets of 1.
People who land here are usually trying to understand whether the GLP-1 social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide and tirzepatide reduce appetite significantly, which can inadvertently lead to inadequate protein intake and reduced physical activity, both of which contribute to lean mass loss and metabolic slowdown during weight loss.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide and tirzepatide reduce appetite significantly, which can inadvertently lead to inadequate protein intake and reduced physical activity, both of which contribute to lean mass loss and metabolic slowdown during weight loss. Weight plateaus in this context often reflect a combination of adaptive thermogenesis, reduced non-exercise activity, and suboptimal dietary composition rather than medication failure alone. Clinicians generally recommend structured protein targets and resistance training alongside GLP-1 therapy to preserve muscle mass and support long-term weight maintenance.
  • Adaptive thermogenesis during weight loss is a real biological phenomenon documented by Leibel et al. (1995, NEJM), meaning plateaus are not always the result of behavioral lapses.
  • Research supports protein targets of 1.2 to 1.6 grams per kilogram of body weight during weight loss to preserve lean mass, but GLP-1-induced appetite suppression can make this harder to achieve.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Adaptive thermogenesis during weight loss is a real biological phenomenon documented by Leibel et al. (1995, NEJM), meaning plateaus are not always the result of behavioral lapses.
  • Research supports protein targets of 1.2 to 1.6 grams per kilogram of body weight during weight loss to preserve lean mass, but GLP-1-induced appetite suppression can make this harder to achieve.
  • Non-exercise activity thermogenesis (NEAT) can account for hundreds of calories per day, and its decline during caloric restriction is a legitimate, documented driver of metabolic slowdown.
  • Wharton et al. (2023, Obesity) found that higher physical activity levels were associated with better body composition outcomes in semaglutide users, supporting the resistance training recommendation.
  • Daily scale weight reflects glycogen stores, water retention, bowel contents, and inflammation, none of which are fat, making single-day readings unreliable indicators of fat loss progress.
  • Jumping to a higher GLP-1 dose as the first response to a plateau is not supported as a first-line strategy before addressing protein intake, activity levels, and other behavioral factors.
  • If a plateau persists after addressing diet and activity, clinicians should evaluate thyroid function, sleep quality, and cortisol, which are biological variables independent of patient behavior.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @lizglpguide actually say?

The creator, a PA who identifies as a GLP-1 user herself, argues that most weight stalls on GLP-1 medications are self-inflicted. Her core claims: you're not eating enough protein, you've gotten sedentary, and you're too focused on the scale. "Most stalls are actually behavioral and not biological," she says, and adds that studies show GLP-1 users who prioritize protein and resistance training lose more fat and keep it off longer. She explicitly warns against jumping to a higher dose as the first response to a stall.

The framing is direct and a little blunt, which works. But a few of the claims deserve a closer look before you take them as settled science.

Does the science back this up?

Mostly, yes, though the picture is more complicated than the video lets on. The protein and resistance training claim is the strongest one here, and the evidence is real.

Martens et al. (2022, The American Journal of Clinical Nutrition) found that higher protein intake during energy restriction significantly preserved lean mass. Separately, a 2023 analysis by Wharton et al. in Obesity looked at semaglutide trial data and found that participants who reported higher physical activity levels had meaningfully better body composition outcomes than those who didn't. The "metabolic adaptation" argument, where your body reduces energy expenditure in response to reduced movement and intake, is well-documented. Leibel et al. (1995, New England Journal of Medicine) established this decades ago, and it holds in GLP-1 contexts too.

The scale variability point is also grounded. GLP-1 medications affect gastric emptying and inflammation, both of which influence water retention and transit weight. A number on the scale on any given morning is not a reliable metabolic report card.

What did they get wrong (or right)?

The claim that "most stalls are behavioral and not biological" is probably the most overconfident line in the video. It's not wrong exactly, but it flattens real biology into a motivational slogan.

Weight loss plateaus have well-characterized biological components that aren't the patient's fault. Adaptive thermogenesis, the reduction in resting metabolic rate beyond what body composition changes would predict, has been documented in studies including Rosenbaum and Leibel (2010, International Journal of Obesity). GLP-1 receptor downregulation is also a legitimate pharmacological phenomenon discussed in receptor kinetics literature. Telling someone their plateau is almost certainly behavioral when they may actually be hitting receptor saturation or genuine adaptive thermogenesis isn't just oversimplified. It risks making people feel like failures when the biology itself is working against them.

That said, the protein advice is solid. The resistance training point is well-supported. And pushing back on automatic dose escalation as a first move is genuinely good clinical instinct. Credit where it's due.

What should you actually know?

GLP-1 plateaus are real, common, and not always your fault. Here's what the evidence actually supports.

  • Protein targets matter. Research generally supports 1.2 to 1.6 grams per kilogram of body weight during weight loss to preserve muscle mass. GLP-1-induced appetite suppression can make hitting those numbers harder than it sounds.
  • Non-exercise activity thermogenesis, what the creator calls "moving around the house," accounts for a significant portion of daily energy expenditure. Declines in NEAT during caloric restriction have been documented and contribute to stalls.
  • Resistance training during GLP-1 therapy is not optional if preserving muscle mass matters to you. Muscle is metabolically active tissue. Losing it makes future weight maintenance harder.
  • Before assuming a stall is entirely behavioral, it's worth talking to a clinician. Thyroid function, sleep quality, cortisol patterns, and medication timing all legitimately affect weight loss trajectories.
  • The scale does lie in the short term. Glycogen repletion, water retention from inflammation, and bowel transit time all influence daily weight readings in ways that have nothing to do with fat loss progress.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Liz | GLP💉Coach · TikTok creator

129.8K views on this video

Struggling with the GLP-1 weight loss stall? GLP one plateaus are usually caused by low protein Under eating and reduce movement and metabolic adaptation. Not the medication failing. Learn how to break through a GLP-1 plateau stall the right way without increasing your dose.

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about adaptive thermogenesis during weight loss?

Adaptive thermogenesis during weight loss is a real biological phenomenon documented by Leibel et al. (1995, NEJM), meaning plateaus are not always the result of behavioral lapses.

What does the video say about research supports protein targets of 1.2 to 1.6 grams per?

Research supports protein targets of 1.2 to 1.6 grams per kilogram of body weight during weight loss to preserve lean mass, but GLP-1-induced appetite suppression can make this harder to achieve.

What does the video say about non-exercise activity thermogenesis (neat) can account for hundreds of calories?

Non-exercise activity thermogenesis (NEAT) can account for hundreds of calories per day, and its decline during caloric restriction is a legitimate, documented driver of metabolic slowdown.

What does the video say about wharton et al. (2023, obesity) found?

Wharton et al. (2023, Obesity) found that higher physical activity levels were associated with better body composition outcomes in semaglutide users, supporting the resistance training recommendation.

What does the video say about daily scale weight reflects glycogen stores, water retention, bowel contents,?

Daily scale weight reflects glycogen stores, water retention, bowel contents, and inflammation, none of which are fat, making single-day readings unreliable indicators of fat loss progress.

What does the video say about jumping to a higher glp-1 dose as the first response?

Jumping to a higher GLP-1 dose as the first response to a plateau is not supported as a first-line strategy before addressing protein intake, activity levels, and other behavioral factors.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Liz | GLP💉Coach, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.